Skip to main content
. 2019 Mar 21;42:397–407. doi: 10.1016/j.ebiom.2019.03.032

Fig. 2.

Fig. 2

CDC20 is predominantly enriched in prostate CSCs.

(a–c) The mRNA expression of a series of stemness related genes (CD44, CD133, SOX2, OCT4) was analysed by quantitative real time PCR (qRT-PCR) in adherent and spheroid prostate cancer cell lines C4–2B (a) and DU145 (b); CDC20 mRNA and protein expression were compared between adherent and spheroid cells using qRT-PCR (a, b) and western blot (c) (P value: Wilcoxon test). (d–f) The mRNA expression of a series of stemness related genes (CD44, CD133, SOX2, OCT4) was analysed by qRT-PCR in prostate cancer cell spheroids derived from sorted CD44− and CD44+ of C4–2B (d) and DU145 (e); CDC20 mRNA and protein expression were compared between CD44− and CD44+ cells using qRT-PCR (d, e) and western blot (f) (P value: Wilcoxon test). (g–i) The mRNA expression of a series of stemness related genes (CD44, CD133, SOX2, OCT4) was analysed by qRT-PCR in prostate cancer cell derived from control and docetaxel resistant C4–2B (g) and DU145 (h); CDC20 mRNA and protein expression were compared between control and docetaxel resistant cells (DTX-R) using qRT-PCR (g, h) and western blot (i) (P value: Wilcoxon test). The results were collected from three independent experiments and all data represent Mean ± SD. All p values were defined as: *p < .05, **p < .01 and ***p < .001.